Monitor trading volume and bid-ask spread post-split to assess improved liquidity. Watch for potential Nasdaq compliance update. The reverse split may temporarily attract speculative trading but does not alter fundamentals.
Price Chart
Executive Summary
FibroBiologics, Inc. executed a 1-for-20 reverse stock split effective March 30, 2026, reducing its outstanding shares and increasing the per-share price proportionally. The move is aimed at regaining compliance with Nasdaq listing requirements and improving stock marketability.
Key Facts
- FibroBiologics implemented a 1-for-20 reverse stock split effective March 30, 2026
- The reverse split reduces the number of outstanding shares by a factor of 20 while increasing the per-share price proportionally
- No change to authorized shares, par value, or stockholders' percentage ownership (except for rounding of fractional shares)
- CUSIP changed to 31573L204; ticker symbol FBLG remains unchanged
- All outstanding equity awards and warrants will be proportionally adjusted
Financial Impact
No change to market capitalization ($5M) or equity structure; only share count and price per share are adjusted
Risk Factors
- Reverse splits are often perceived negatively by the market as a sign of financial distress
- Low market cap ($5M) and illiquidity may persist despite the split
- Risk of continued delisting if minimum bid price requirements are not sustained
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142089 |
| Document: fblg-ex3_1.htm | 0001193125-26-142089 |
| Document: 0001193125-26-142089-index-headers.html | 0001193125-26-142089 |
| Document: 0001193125-26-142089-index.html | 0001193125-26-142089 |
| Document: 0001193125-26-142089.txt | 0001193125-26-142089 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers